InvestorsHub Logo
Followers 52
Posts 2237
Boards Moderated 0
Alias Born 07/06/2011

Re: Bad_Timing post# 367331

Tuesday, 07/27/2021 5:07:52 PM

Tuesday, July 27, 2021 5:07:52 PM

Post# of 403480
What are your thoughts on the neutralizing antibodies that directly disrupt viruses outside of cells like brilacidin is believed to do? They are given IV also. Were they successful in treating hospitalized patients? How about in non-hospitalized patients, were they practical to administer?

In theory, antivirals that work outside the cell are best given prophylactically or at the early viral stage of disease. For those already with a good viral infection going, it would be good to inhibit viral replication to lower the viral load, since the viruses already are in the cells. For those with moderate to severe Covid, they are probably past the viral stage of disease and dealing with an immunological over-reaction / hyper inflammatory response (cytokine storm, etc...). Hopefully brilacidin can deal with multiple aspects of SARS2 infection with its multiple (potential) MOAs.


So I don't get your comparison to drugs that only target replication.



Somebody asked. It's pretty simple. Brilacidin shares one possible antiviral MOA with the 3 oral mpro inhibitors in trials.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News